Glycopyrrolate in comparison to hyoscine hydrobromide and placebo in the treatment of hypersalivation induced by clozapine (GOTHIC1): study protocol for a randomised controlled feasibility study
Open Access
- 21 November 2016
- journal article
- research article
- Published by Springer Nature in Trials
- Vol. 17 (1) , 1-9
Abstract
Clozapine is the only medication licensed for the treatment of resistant schizophrenia in the UK. Although efficacious, a common and unpopular side effect of clozapine treatment is clozapine-induced hypersalivation (CIH), which can contribute to non-adherence. The standard treatment for CIH in the UK is hyoscine hydrobromide but this may aggravate cognitive deficits in patients with schizophrenia while glycopyrrolate may be an effective alternative with a more tolerable side effect profile. There is currently no convincing evidence for hyoscine, or any other medication, as an effective treatment for CIH. This is a multicentre randomised, double-blind, placebo-controlled feasibility study of glycopyrronium bromide (glycopyrrolate) and hyoscine hydrobromide (hyoscine) in patients with clozapine-induced hypersalivation. We aim to recruit 42 patients who have been prescribed clozapine and are experiencing hypersalivation, and randomise them to one of three study arms (either hyoscine, glycopyrrolate or placebo). The primary outcome measures will be the participant recruitment and attrition rates, and the secondary outcome will be the metrics of the daytime hypersalivation measure. After a 1-week washout period (discontinuing CIH medication, if any), there will be a 4-week treatment period where participants will be titrated up to the maximum tolerated dose of hyoscine, glycopyrrolate or placebo. Measurements of daytime salivation, nocturnal salivation, cognition and side effects will be taken during home visits in week 2 and week 5. Information on salivation and side effects will also be taken through telephone calls in week 3 and week 4. To gather information on the experience of study participants, exit interviews will also be requested with all participants who drop out of the study and a sample of participants who complete the study. There is currently no convincing evidence for hyoscine, or any other medication, as an effective treatment for CIH. There is promising evidence that glycopyrrolate may be more successful in the treatment of CIH causing fewer cognitive side effects. We propose to conduct a randomised placebo-controlled feasibility study of glycopyrrolate and hyoscine in the treatment of clozapine-induced hypersalivation to inform the design of a future efficacy trial. Clinicaltrials.gov NCT02613494 , 23 November 2015.Keywords
Funding Information
- National Institute for Health Research (PB-PG-0214-33069)
This publication has 25 references indexed in Scilit:
- Safety and efficacy of glycopyrrolate oral solution for management of pathologic drooling in pediatric patients with cerebral palsy and other neurologic conditionsTherapeutics and Clinical Risk Management, 2012
- Recommendations for Planning Pilot Studies in Clinical and Translational ResearchClinical and Translational Science, 2011
- Oral glycopyrrolate for the treatment of chronic severe drooling caused by neurological disorders in childrenNeuropsychiatric Disease and Treatment, 2011
- Management of drooling in children: a survey of UK paediatricians' clinical practiceChild: Care, Health and Development, 2011
- Comparison of the efficacy and impact on cognition of glycopyrrolate and biperiden for clozapine-induced sialorrhea in schizophrenic patients: A randomized, double-blind, crossover studySchizophrenia Research, 2010
- Glycopyrrolate for Treatment of Clozapine-Induced Sialorrhea in Three AdolescentsJournal of Child and Adolescent Psychopharmacology, 2008
- Sample size of 12 per group rule of thumb for a pilot studyPharmaceutical Statistics, 2005
- Scopolamine impairs human recognition memory: Data and modeling.Behavioral Neuroscience, 2003
- Aspiration Pneumonia Possibly Secondary to Clozapine-Induced SialorrheaJournal of Clinical Psychopharmacology, 1996
- A Self-Rating Scale for Measuring Neuroleptic Side-EffectsThe British Journal of Psychiatry, 1995